Nilutamide
Nilandron · Anandron
Half-life
2.1 days
Time to Peak
3 hr
Steady State
~11 days
Dose Range
150–300 mg
Frequency
Daily
Overview
First-generation non-steroidal anti-androgen used for prostate cancer. Rarely used due to unique side effects including delayed dark adaptation (visual disturbance in ~25% of patients) and rare interstitial pneumonitis.
Mechanism of Action
Non-steroidal androgen receptor antagonist.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Oral | 150–300 mg | 2.1 days | 3 hr | Daily |
Used in Regimens
Nilutamide is not currently part of any catalog regimen.
Data Sources
- FDA Label Nilandron (nilutamide) FDA Prescribing Information
Related Tools
Track Nilutamide with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.